<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>åˆ¶è¯æ—¥æŠ¥ - 2026-01-19</title>
    <style>
        :root {
            --bg-primary: #ffffff;
            --bg-secondary: #f5f5f7;
            --text-primary: #1d1d1f;
            --text-secondary: #86868b;
            --accent: #0071e3;
            --accent-hover: #0077ed;
            --border: #d2d2d7;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.05);
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "SF Pro Display", "SF Pro Text", "Helvetica Neue", "PingFang SC", "Microsoft YaHei", sans-serif;
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.5;
            -webkit-font-smoothing: antialiased;
        }

        .container {
            max-width: 980px;
            margin: 0 auto;
            padding: 0 22px;
        }

        /* Header */
        header {
            padding: 80px 0 60px;
            text-align: center;
        }

        .logo {
            font-size: 48px;
            margin-bottom: 16px;
        }

        h1 {
            font-size: 48px;
            font-weight: 600;
            letter-spacing: -0.02em;
            margin-bottom: 8px;
        }

        .subtitle {
            font-size: 21px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        /* Stats */
        .stats-bar {
            display: flex;
            justify-content: center;
            gap: 48px;
            padding: 32px 0;
            margin: 40px 0;
            border-top: 1px solid var(--border);
            border-bottom: 1px solid var(--border);
        }

        .stat {
            text-align: center;
        }

        .stat-value {
            font-size: 32px;
            font-weight: 600;
            color: var(--text-primary);
        }

        .stat-label {
            font-size: 14px;
            color: var(--text-secondary);
            margin-top: 4px;
        }

        /* Analysis Section */
        .analysis {
            background: var(--bg-secondary);
            border-radius: 18px;
            padding: 32px;
            margin-bottom: 48px;
        }

        .analysis h2 {
            font-size: 24px;
            margin-bottom: 16px;
        }

        .analysis-content {
            font-size: 17px;
            line-height: 1.7;
            color: var(--text-secondary);
        }

        /* Category Section */
        .category {
            margin-bottom: 56px;
        }

        .category-header {
            display: flex;
            align-items: baseline;
            gap: 12px;
            margin-bottom: 24px;
            padding-bottom: 12px;
            border-bottom: 1px solid var(--border);
        }

        .category-title {
            font-size: 28px;
            font-weight: 600;
        }

        .category-title-en {
            font-size: 17px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        .category-count {
            background: var(--bg-secondary);
            color: var(--text-secondary);
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 14px;
            margin-left: auto;
        }

        /* News Card */
        .news-card {
            background: var(--bg-primary);
            border: 1px solid var(--border);
            border-radius: 18px;
            padding: 28px;
            margin-bottom: 16px;
            transition: all 0.3s ease;
        }

        .news-card:hover {
            box-shadow: var(--card-shadow);
            transform: translateY(-2px);
        }

        .news-card h3 {
            font-size: 21px;
            font-weight: 600;
            margin-bottom: 12px;
            line-height: 1.4;
        }

        .news-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 16px;
            margin-bottom: 16px;
            font-size: 14px;
            color: var(--text-secondary);
        }

        .news-source {
            color: var(--accent);
            font-weight: 500;
        }

        .news-importance {
            letter-spacing: 2px;
        }

        .news-summary {
            font-size: 17px;
            color: var(--text-secondary);
            line-height: 1.6;
            margin-bottom: 16px;
        }

        .news-link {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            color: var(--accent);
            text-decoration: none;
            font-size: 17px;
            font-weight: 500;
            transition: color 0.2s;
        }

        .news-link:hover {
            color: var(--accent-hover);
        }

        .news-link::after {
            content: "â†’";
            transition: transform 0.2s;
        }

        .news-link:hover::after {
            transform: translateX(4px);
        }

        /* Footer */
        footer {
            text-align: center;
            padding: 48px 0;
            color: var(--text-secondary);
            font-size: 14px;
            border-top: 1px solid var(--border);
            margin-top: 48px;
        }

        footer p {
            margin-bottom: 8px;
        }

        /* Language Flag */
        .lang-flag {
            font-size: 16px;
            margin-right: 8px;
        }

        /* Date Filter */
        .date-filter {
            display: flex;
            justify-content: center;
            gap: 8px;
            flex-wrap: wrap;
            margin-bottom: 32px;
        }

        .date-btn {
            padding: 8px 16px;
            border: 1px solid var(--border);
            border-radius: 20px;
            background: var(--bg-primary);
            color: var(--text-secondary);
            font-size: 14px;
            cursor: pointer;
            transition: all 0.2s ease;
            display: flex;
            flex-direction: column;
            align-items: center;
            min-width: 70px;
        }

        .date-btn:hover {
            border-color: var(--accent);
            color: var(--accent);
        }

        .date-btn.active {
            background: var(--accent);
            border-color: var(--accent);
            color: white;
        }

        .date-btn.weekend {
            background: var(--bg-secondary);
        }

        .date-btn.weekend.active {
            background: var(--accent);
        }

        .date-btn .weekday {
            font-size: 12px;
            opacity: 0.8;
        }

        .date-btn .date-display {
            font-weight: 500;
        }

        .filter-count {
            text-align: center;
            color: var(--text-secondary);
            font-size: 14px;
            margin-bottom: 24px;
        }

        .news-card.hidden {
            display: none;
        }

        /* Responsive */
        @media (max-width: 734px) {
            header {
                padding: 48px 0 40px;
            }

            h1 {
                font-size: 32px;
            }

            .subtitle {
                font-size: 17px;
            }

            .stats-bar {
                gap: 24px;
            }

            .stat-value {
                font-size: 24px;
            }

            .category-title {
                font-size: 24px;
            }

            .news-card {
                padding: 20px;
            }

            .news-card h3 {
                font-size: 19px;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <header>
            <div class="logo">ğŸ’Š</div>
            <h1>åˆ¶è¯æ—¥æŠ¥</h1>
            <p class="subtitle">Pharma Daily Â· 2026-01-19</p>
        </header>

        <div class="stats-bar">
            <div class="stat">
                <div class="stat-value">99</div>
                <div class="stat-label">æ–°é—»æ€»æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">4</div>
                <div class="stat-label">ç±»åˆ«æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">2026-01-19 23:31</div>
                <div class="stat-label">æ›´æ–°æ—¶é—´</div>
            </div>
        </div>

        <!-- Date Filter -->
        <div class="date-filter">
            <button class="date-btn active" data-filter="all">
                <span class="weekday">å…¨éƒ¨</span>
                <span class="date-display">All</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-13">
                <span class="weekday">å‘¨äºŒ</span>
                <span class="date-display">01/13</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-14">
                <span class="weekday">å‘¨ä¸‰</span>
                <span class="date-display">01/14</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-15">
                <span class="weekday">å‘¨å››</span>
                <span class="date-display">01/15</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-16">
                <span class="weekday">å‘¨äº”</span>
                <span class="date-display">01/16</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-17">
                <span class="weekday">å‘¨å…­</span>
                <span class="date-display">01/17</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-18">
                <span class="weekday">å‘¨æ—¥</span>
                <span class="date-display">01/18</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-19">
                <span class="weekday">å‘¨ä¸€</span>
                <span class="date-display">01/19</span>
            </button>
            
        </div>
        <div class="filter-count" id="filterCount"></div>

        
        <section class="analysis">
            <h2>ğŸ“Š æœ¬å‘¨æ¦‚è§ˆ</h2>
            <div class="analysis-content">
                <h3>ğŸ“Š AI æ™ºèƒ½åˆ†æ</h3>
<h4>æœ¬å‘¨æ¦‚è§ˆ</h4>
<p>2026-01-19 å…±è·å– 99 æ¡åˆ¶è¯è¡Œä¸šæ–°é—»ï¼Œæ¶µç›– 4 ä¸ªç±»åˆ«ã€‚</p>
<h4>ğŸ”¥ é‡ç‚¹æ–°é—»</h4>
<p><strong>1. FDA delays decision on Travere's Filspari in key kidney disease indication</strong> â­â­â­â­<br>
   - ç±»åˆ«: ç»¼åˆ<br>
   - æ¥è‡ª FiercePharma</p>
<p><strong>2. Makary talks FDA's plans to combat China's biotech growth</strong> â­â­â­â­<br>
   - ç±»åˆ«: æ–°è¯ç ”å‘<br>
   - æ¥è‡ª Endpoints News</p>
<p><strong>3. The newest womenâ€™s health unicorn</strong> â­â­â­â­<br>
   - ç±»åˆ«: æ–°è¯ç ”å‘<br>
   - æ¥è‡ª Endpoints News</p>
<p><strong>4. Novo Nordisk Foundation to inject $850M+ into BioInnovation Institute through 2035</strong> â­â­â­â­<br>
   - ç±»åˆ«: æ–°è¯ç ”å‘<br>
   - æ¥è‡ª Endpoints News</p>
<p><strong>5. STAT+: Pharmalittle: Weâ€™re reading about antitrust claims by a compounder, FDA and EMA AI rules, and more</strong> â­â­â­â­<br>
   - ç±»åˆ«: ç»¼åˆ<br>
   - æ¥è‡ª STAT News - Pharma</p>
<h4>ğŸ“ åˆ†ç±»æ‘˜è¦</h4>
<p><strong>ç»¼åˆ</strong> (): å…± 38 æ¡æ–°é—»<br>
<strong>æ–°è¯ç ”å‘</strong> (Drug R&D): å…± 34 æ¡æ–°é—»<br>
<strong>ç›‘ç®¡å®¡æ‰¹</strong> (Regulatory): å…± 20 æ¡æ–°é—»<br>
<strong>å•†ä¸šåŠ¨æ€</strong> (Business/M&A): å…± 7 æ¡æ–°é—»</p>
<h4>ğŸ”® æ˜æ—¥å…³æ³¨</h4>
<p>è¯·å…³æ³¨å„ç±»ä¸´åºŠè¯•éªŒæ•°æ®æ›´æ–°å’Œç›‘ç®¡å®¡æ‰¹è¿›å±•ã€‚</p>
            </div>
        </section>
        

        <main>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç»¼åˆ</h2>
                    <span class="category-title-en"></span>
                    <span class="category-count">38 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA delays decision on Travere&#39;s Filspari in key kidney disease indication
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-14 10:44</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Much is riding on Travere Therapeuticsâ€™ bid to gain an expansion for Filspari to treat focal segmental glomerulosclerosis (FSGS). The indication represents a $2 billion peak sales opportunity in the U.S. alone, according to Leerink Partners. So it was with some trepidation that Travere revealed that the FDA has postponed its decision on Filspari in FSGS by three months to April 13.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/fda-delays-decision-traveres-filspari-2b-kidney-disease-indication" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about antitrust claims by a compounder, FDA and EMA AI rules, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-15 14:12</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA delayed reviews of two drugs chosen for the Trump administration&#39;s new fast-track program after agency scientists flagged safety and efficacy concerns</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/15/fda-antitrust-lilly-novo-compounders-insulin-ai-novartis/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-13">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        JPM26: AstraZeneca&#39;s $80B revenue target &#39;very much within reach,&#39; CFO says
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-13 23:32</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">While the $80 billion revenue target AstraZeneca set for 2030 is already &#34;very much within reach,&#34; Chief Financial Officer Aradhana Sarin said the company would grow even more confident if it can repeat the phase 3 success rate it saw last year.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/astrazeneca-80-billion-revenue-target-very-much-within-reach-cfo-says" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug approvals went from crawl to sprint in 2025
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 16:37</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">On this episode of &#34;The Top Line,&#34; we dig into how turmoil at the FDA impacted drug approvals in 2025.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/drug-approvals-went-crawl-sprint-2025" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA tells Sanofi, GSK, AZ and CSL to include warnings for febrile seizures on flu shot labels
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 11:11</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA has told the makers of six flu vaccines that they need to add a notification to the label of their shots, warning of the risk of febrile seizures which can occur after childhood vaccinations and typically last no more than a few minutes and are generally harmless.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/fda-tells-sanofi-gsk-az-and-csl-include-warning-childhood-seizures-flu-shots" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA chides BeOne, ImmunityBio promo materials in 1st untitled letters of 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 11:21</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The steady stream of FDA untitled letters that began in September is showing no signs of letting up in the new year.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/fda-chides-beone-immunitybio-promo-materials-first-untitled-letters-2026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        JPM26: Astellas CEO resists &#39;rescue BD&#39; as $6B Xtandi patent cliff nears
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 01:31</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">With Xtandi set to lose U.S. patent protection next year, Astellasâ€™ CEO fielded questions this week about his companyâ€™s dealmaking strategy ahead of the loss. Despite continuing to hunt for external innovation, helmsman Naoki Okamura does not want Astellas to make acquisitions for the sole purpose of preventing a revenue decline.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/astellas-ceo-resists-rescue-bd-6b-xtandi-patent-cliff-nears" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        BD budgets $110M to expand Neb. syringe production
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 08:06</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Becton, Dickinson and Company will shell out $110 million to expand prefillable syringe production at its Columbus, Nebraska, manufacturing plant. The move comes in response to increasing delivery demands for GLP-1s, plus broader conversations about pharmaceutical reshoring in the U.S., the company said.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/becton-dickinson-budgets-110m-expand-nebraska-syringe-production-plant" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        JPM26: Jazz&#39;s $200M voucher sale shows drumbeat of rising prices isn&#39;t stopping
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-14 15:23</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Even in the era of the FDA&#39;s Commissioner&#39;s National Priority Voucher program, Jazz Pharmaceuticals is showing that traditional priority review vouchers can catch a pretty penny.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/jpm26-jazzs-prv-sale-200m-shows-drum-beat-rising-prv-prices-isnt-stopping" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Amneal and VantAI unveil fresh branding to kick off 2026 plans
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-14 11:05</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Amneal Pharmaceuticals and VantAI have joined the ranks of companies to decide that a new year demands a new look, each unveiling fresh branding aligned with their respective plans for 2026.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/amneal-and-vantai-unveil-fresh-branding-kick-2026-plans" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: FDA delays reviews for two drugs in new voucher program
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 14:36</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">And more biotech news, brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/16/biotech-news-fda-delays-review-in-voucher-program/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about FDA voucher worries, weight loss drugs and jet fuel, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 14:30</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Some major drugmakers are hesitating to participate in the Trump administration&#39;s speedier review program for new medicines over possible legal risks</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/16/trump-fda-voucher-obesity-novo-lilly-covid/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about a change in obesity drug warnings, FDA approvals, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-14 14:20</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">After an agency review, the FDA asked drugmakers to remove warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight loss drugs</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/14/obesity-weight-suicide-illumina-antibiotics-pfizer-lilly-novo/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-13">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about a â€˜breachedâ€™ FDA firewall, an AbbVie pricing deal with Trump, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-13 14:22</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A veteran FDA regulator who left last month said the firewall between agency political appointees and drug reviewers â€œhas been breached&#34;</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/13/fda-trump-abbvie-cvs-hiv-lilly-nvidia-abortion/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-16 10:16</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the horizon and a growing pipeline, the Cabometyx maker is aiming big.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/single-product-exelixis-aims-be-top-5-solid-tumor-drugmaker-us" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lenz ups Vizz visibility with DTC campaign starring Sarah Jessica Parker
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-14 11:18</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">As part of its mission to make a dent in the sizable presbyopia market, Lenz Therapeutics has scoped out a star-studded partnership for its Vizz prescription eye drops.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/lenz-ups-vizz-visibility-dtc-campaign-starring-sarah-jessica-parker" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        From approval to value: Why evidence storytelling now matters
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 15:46</span>
                        
                    </div>
                    
                    <p class="news-summary">RTI Health Solutions experts explain how HEOR and real-world evidence are reshaping access decisionsâ€”and why clear communication is essential.</p>
                    
                    <a href="https://www.fiercepharma.com/sponsored/approval-value-why-evidence-storytelling-now-matters" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        After AbbVie and Genmab&#39;s ph. 3 survival miss for Epkinly in DLBCL, what&#39;s next?
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-16 15:29</span>
                        
                    </div>
                    
                    <p class="news-summary">Just days after AbbVie unveiled a major new oncology play in the form of its high-dollar RemeGen collab, the Illinois drugmaker closed out the week with some mixed news for marketed cancer offering Epkinly.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/after-abbvie-and-genmabs-ph-3-survival-miss-epkinly-dlbcl-whats-next" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        JPM26: Fujifilm CEO touts biologics capacity edge amid expansion tear
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-16 10:52</span>
                        
                    </div>
                    
                    <p class="news-summary">With Fujifilm Biotechnologies now among the top echelon of CDMOs by biologics capacity, Fujifilmâ€™s group CEO reflected on the unitâ€™s unique facility design philosophy and how itâ€™s eschewing big M&amp;amp;A plays to expand in-house.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/jpm26-fujifilm-ceo-touts-biologics-capacity-edge-manufacturing-unit-keeps-expansions-coming" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AbbVieâ€™s Skyrizi takes full-year TV ad spending crown yet again, with J&amp;amp;Jâ€™s Tremfya in hot pursuit
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-16 10:49</span>
                        
                    </div>
                    
                    <p class="news-summary">For the fourth year runningâ€”and the third in a row for Skyrizi specificallyâ€”an AbbVie immunology med has claimed the top spot in the full-year TV drug ad spending rankings.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/abbvies-skyrizi-takes-full-year-tv-ad-spending-crown-yet-again-jjs-tremfya-hot-pursuit" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Fierce Pharma Asiaâ€”AbbVieâ€™s bispecific play, Illuminaâ€™s China import efforts and pharma execsâ€™ JPM comments
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 10:47</span>
                        
                    </div>
                    
                    <p class="news-summary">In this week&#39;s Asia news recap, AbbVie struck a big deal to enter the hot PD-1xVEGF bispecific space, while Illumina&#39;s CEO detailed the company&#39;s efforts to work with authorities in China. In addition, Astellas CEO Naoki Okamura updated the audience at Fierce JPM Week on the company&#39;s approach to dealmaking.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/fierce-pharma-asia-abbvies-bispecific-play-illuminas-china-import-efforts-and-pharma-execs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Former Emergent CEO Kramer faces insider trading allegations in NY
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 16:21</span>
                        
                    </div>
                    
                    <p class="news-summary">New York&#39;s attorney general has filed an insider trading lawsuit against former Emergent BioSolutions CEO Robert Kramer, accusing him of selling company shares and receiving more than $10 million before the company revealed contamination issues at a plant in Baltimore. As part of the action, New York also announced a $900,000 million settlement with the company.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/former-emergent-ceo-kramer-faces-insider-trading-allegations-ny" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        JPM26: Whatâ€™s in a biopharma? CEO says Teva has the goods
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 15:17</span>
                        
                    </div>
                    
                    <p class="news-summary">Under CEO Richard Francis, Teva has long been looking to reframe itself as an innovative drugmaker on par with industry peers. Now, Francis says the company is on track to complete its transformation into a leading innovative biopharma company.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/jpm-2026-biosimilars-biopharma-teva-walks-walk-2026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Trump takes aim at insurance industry, drug prices in unveiling &#39;The Great Healthcare Plan&#39;
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 12:47</span>
                        
                    </div>
                    
                    <p class="news-summary">President Donald Trump has hinted at &#34;concepts of a plan&#34; for healthcare for months as legislators debate the future of key subsidies under the Affordable Care Act, and on Thursday the White House unveiled a more concrete version of their vision for health policy.</p>
                    
                    <a href="https://www.fiercepharma.com/regulatory/trump-takes-aim-insurance-industry-unveiling-great-healthcare-plan" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        After succeeding in combo with Darzalex, J&amp;amp;J&#39;s Tecvayli shines as solo act
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 07:45</span>
                        
                    </div>
                    
                    <p class="news-summary">Just a month after Johnson &amp;amp; Johnson reported a successful study pairing its blood cancer treatments Tecvayli and Darzalex, the company has revealed another trial win. This time, Tecvayli excelled as a solo agent, reducing the risk of disease progression or death by 71% over standard of care in a group of multiple myeloma patients resistant to anti-CD38 therapy.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/after-succeeding-combo-darzalex-jjs-tecvayli-shines-solo-act" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Hologic sets a screen to block cervical cancer with WNBA&#39;s Erica Wheeler
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 06:58</span>
                        
                    </div>
                    
                    <p class="news-summary">Hologic has drafted professional basketball player Erica Wheeler to raise awareness of cervical cancer screening, putting the guard at the center of a drive to frame testing as the â€œUltimate Defense.â€</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/hologic-sets-screen-block-cervical-cancer-basketball-star" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bayer taps Gabrielle Union-Wade as face of menopause med Lynkuet
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-14 15:06</span>
                        
                    </div>
                    
                    <p class="news-summary">To promote its newly launched nonhormonal menopause drug, Bayer is linking Lynkuet with a familiar face.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/bayer-taps-gabrielle-union-wade-face-menopause-med-lynkuet" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        JPM26: With pricing deal in the books, Sanofi steels against lingering policy unknowns
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-14 14:30</span>
                        
                    </div>
                    
                    <p class="news-summary">With a White House drug pricing deal done and dusted and the threat of tariffs ameliorated, Sanofi is now enjoying more clarity from the federal government than at the same time last year. But several concerns still linger for the French pharma as the calendar turns to 2026.</p>
                    
                    <a href="https://www.fiercepharma.com/biotech/jpm26-after-important-year-sanofi-looks-ahead-remaining-federal-challenges" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        JPM26: Novo Nordisk CEO reflects on &#39;curse of a leader&#39; as company looks to reassert GLP-1 footing
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-14 09:32</span>
                        
                    </div>
                    
                    <p class="news-summary">The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out for 2026, new CEO Maziar Mike Doustdar appears confident in his commercial and R&amp;amp;D battle plan for the coming months.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/jpm26-novo-nordisk-ceo-reflects-curse-leader-company-looks-reassert-glp-1-footing" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Supreme Court agrees to review â€˜skinny labelingâ€™ and generic drug access
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 21:03</span>
                        
                    </div>
                    
                    <p class="news-summary">The Supreme Court agreed to review a controversy over so-called skinny labels for medicines, a decision that will be closely watched for its implications for the availability of generic medicines.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/16/scotus-generics-patents-supreme-court-amarin-hikma/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Up and down the ladder: The latest comings and goings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 17:00</span>
                        
                    </div>
                    
                    <p class="news-summary">From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/16/pharma-biotech-jobs-novo-bristol-astrazeneca/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Trump releases health care plan amid pressure over affordability
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-15 18:10</span>
                        
                    </div>
                    
                    <p class="news-summary">Trump&#39;s most consequential proposals would require action from Congress.</p>
                    
                    <a href="https://www.statnews.com/2026/01/15/trump-great-healthcare-plan-potential-stumbling-blocks/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Former Emergent BioSolutions CEO sued for insider trading, company reaches $900K settlement in N.Y.
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-15 17:55</span>
                        
                    </div>
                    
                    <p class="news-summary">The former CEO of Emergent BioSolutions was accused of insider trading by the New York attorney general in connection with a Covid-era contract.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/15/covid-insider-trading-stock-emergent-astrazeneca/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmacy compounder files antitrust lawsuit against Eli Lilly and Novo Nordisk
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-15 01:29</span>
                        
                    </div>
                    
                    <p class="news-summary">A compounding pharmacy has filed a lawsuit accusing Eli Lilly and Novo Nordisk of using anticompetitive tactics to prevent it from serving patients.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/14/pharmacy-compounder-antitrust-lilly-novo-weight-obesity/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-13">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: HHS dismisses members of vaccine injury advisory panel
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-13 21:24</span>
                        
                    </div>
                    
                    <p class="news-summary">RFK Jr. is considering changes to the federal vaccine injury compensation program.</p>
                    
                    <a href="https://www.statnews.com/2026/01/13/hhs-dismisses-veronica-mcnally-advisory-commission-on-childhood-vaccinations/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-13">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: At JPM 2026, Mehmet Oz and top Trump health officials explain their thinking to hospital leaders
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-13 16:32</span>
                        
                    </div>
                    
                    <p class="news-summary">Oz downplayed the effects of cuts to Medicaid and defended RFK Jr.&#39;s moves on vaccines.</p>
                    
                    <a href="https://www.statnews.com/2026/01/13/jpm-2026-cms-officials-face-off-hospital-insurance-execs/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-13">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Illumina launches massive cell atlas to fast-track drug discovery
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-13 13:15</span>
                        
                    </div>
                    
                    <p class="news-summary">The genomics juggernaut Illumina has launched a massive cell atlas to fast-track drug discovery.</p>
                    
                    <a href="https://www.statnews.com/2026/01/13/illumina-billion-cell-atlas-ai-drug-development/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-13">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Unitaid will provide funds for South Africa and Zambia to widen access to Gileadâ€™s HIV prevention drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-13 11:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Unitaid will provide funds for South Africa and Zambia to widen access to Gilead&#39;s HIV prevention drug.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/13/aids-hiv-gilead-unitaid-africa-lenacapavir/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">æ–°è¯ç ”å‘</h2>
                    <span class="category-title-en">Drug R&amp;D</span>
                    <span class="category-count">34 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Makary talks FDA&#39;s plans to combat China&#39;s biotech growth
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 19:51</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">As China sees increased biotech investments, licensing deals and faster early-phase clinical trial starts, FDA Commissioner Marty Makary said his agency is reworking Phase 1 trial regulations to speed that entry process and tweaking user ...</p>
                    
                    <a href="https://endpoints.news/makary-talks-fdas-plans-to-combat-chinas-biotech-growth/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The newest womenâ€™s health unicorn
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-15 19:00</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Last week, Pomelo Care kicked off the year by raising $92 million in a Series C round that valued it at $1.7 billion â€” becoming digital healthâ€™s first newly minted unicorn of 2026, by my count ...</p>
                    
                    <a href="https://endpoints.news/the-newest-womens-health-unicorn/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo Nordisk Foundation to inject $850M+ into BioInnovation Institute through 2035
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-15 08:30</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The Novo Nordisk Foundation is committing 5.5 billion Danish krone ($857 million) to a life science and deep tech incubator called the BioInnovation Institute from 2026 through 2035. The funding will allow the institute, also ...</p>
                    
                    <a href="https://endpoints.news/novo-nordisk-foundation-to-inject-850m-into-bioinnovation-institute-through-2035/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-16 16:24</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">More than 3,000 prescriptions were written for Novo&amp;rsquo;s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached a settlement over a trading scandal and Sanofi is reportedly circling an eye drug biotech.</p>
                    
                    <a href="https://www.biopharmadive.com/news/wegovy-pill-sales-emergent-sanofi-ocular-jazz-novo/809709/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharmaâ€™s cell therapy view
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-14 19:59</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Drugmaker CEOs see online sales channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect a rebound in new stock offerings.&amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/news/jpm26-biotech-ipos-novo-wegovy-gsk-cell-therapy/809600/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-14 16:51</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a &amp;ldquo;rapid review&amp;rdquo; for orforglipron that&#39;s currently speeding along &amp;ldquo;at pace.&amp;rdquo;&amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/news/lilly-obesity-pill-orforglipron-fda-decision-dtc-sales/809598/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Agomab and SpyGlass file for IPOs as investor enthusiasm builds after JPM
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 22:05</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">SpyGlass Pharma and Agomab Therapeutics filed for initial public offerings on Friday evening. The drug developers hope to build on the strong start set by Aktis Oncologyâ€™s $318 million Nasdaq listing last ...</p>
                    
                    <a href="https://endpoints.news/agomab-and-spyglass-file-for-ipos-as-investor-enthusiasm-builds-after-jpm/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drugmakers without MFN pacts are bracing to make one
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 20:48</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">All but 17 drugmakers avoided a direct demand from President Donald Trump last year to lower their prices significantly. But that likely wonâ€™t last. There was a subtle unease among executives of some of the ...</p>
                    
                    <a href="https://endpoints.news/drugmakers-without-mfn-pacts-are-bracing-to-make-one/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        European regulators recommended 38 novel drugs in 2025, 15 fewer than the FDA
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 12:10</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The European Medicines Agency recommended 104 medicines for approval in 2025, the second-highest number in the past 15 years, according to a report the agency published Thursday. Of the positive recommendations ...</p>
                    
                    <a href="https://endpoints.news/european-regulators-recommended-38-novel-drugs-in-2025-15-fewer-than-the-fda/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA to meet Novo Nordisk on troubled site; AbbVie buys drug-device factory
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-15 13:52</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA is set to meet with Novo Nordisk sometime early this year to discuss the progress made at its troubled Indiana facility, formerly run by Catalent. This is according to ...</p>
                    
                    <a href="https://endpoints.news/fda-to-meet-novo-nordisk-on-troubled-site-abbvie-buys-drug-device-factory/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Scribe Therapeutics plans to test cholesterol-lowering therapy this summer
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-14 21:11</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Scribe Therapeutics, founded almost nine years ago to develop medicines based on novel CRISPR enzymes, is getting ready to test its first therapy in the clinic this summer, the gene editing startup told Endpoints News ...</p>
                    
                    <a href="https://endpoints.news/scribe-therapeutics-plans-to-test-cholesterol-lowering-therapy-this-summer/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Health tech funding rounds get bigger when Andreessen Horowitz and General Catalyst join
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-14 18:43</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A few venture capital firms make up a significant portion of health tech startup funding, a report by digital health consultancy Rock Health found. The split between startups landing megarounds of over ...</p>
                    
                    <a href="https://endpoints.news/health-tech-funding-rounds-get-bigger-when-andreessen-horowitz-and-general-catalyst-join/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AbbVie, Genmab say Epkinly didn&#39;t prolong overall survival in lymphoma study
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 21:01</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">AbbVie and Genmabâ€™s cancer drug Epkinly failed to improve overall survival in a late-stage study for diffuse large B cell lymphoma. The Phase 3 trial enrolled patients who had received at least one prior therapy ...</p>
                    
                    <a href="https://endpoints.news/abbvie-genmab-say-epkinly-didnt-prolong-overall-survival-in-lymphoma-study/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ImmunityBio&#39;s cell therapy posts encouraging early data in rare blood cancer
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 16:05</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">ImmunityBioâ€™s off-the-shelf cell therapy has shown early promise in a small trial in a rare form of lymphoma. The ongoing Phase 1 study, named QUILT-106, has so far signed up four patients with WaldenstrÃ¶m non ...</p>
                    
                    <a href="https://endpoints.news/immunitybio-cell-therapy-posts-encouraging-early-data-in-rare-blood-cancer/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Ocugen touts Phase 2 data for eye disease gene therapy
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-15 13:15</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Eye disease gene therapy developer Ocugen reported positive interim Phase 2 data for its geographic atrophy program from a small number of patients. Researchers were testing two different dose levels of the experimental therapy, which ...</p>
                    
                    <a href="https://endpoints.news/ocugen-touts-phase-2-data-for-eye-disease-gene-therapy/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        J&amp;J reports positive Phase 3 data for Tecvayli in earlier blood cancer setting
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-15 11:52</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Johnson &amp;amp; Johnsonâ€™s Tecvayli has achieved survival outcomes in a Phase 3 trial that bode well for its ambitions to expand its use to earlier lines of multiple myeloma. The MajesTEC-9 study enrolled patients with ...</p>
                    
                    <a href="https://endpoints.news/jj-reports-positive-phase-3-data-for-tecvayli-in-earlier-blood-cancer-setting/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        On biotechâ€™s biggest stage, renewed excitement gets a stress test
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-16 11:43</span>
                        
                    </div>
                    
                    <p class="news-summary">A surge in deals and financings had the industry abuzz heading into this year&amp;rsquo;s J.P. Morgan Healthcare Conference. But some aren&amp;rsquo;t sure if the rebound is here to stay.</p>
                    
                    <a href="https://www.biopharmadive.com/news/jpm26-biotech-startups-deals-venture-ipo-fda-china/809809/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Trump unveils healthcare affordability plan
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-15 20:30</span>
                        
                    </div>
                    
                    <p class="news-summary">The &amp;ldquo;Great Healthcare Plan&amp;rdquo; is vague, but would send money directly to ACA enrollees and entrench the pricing deals the administration has cut with more than a dozen drugmakers.</p>
                    
                    <a href="https://www.biopharmadive.com/news/trump-great-healthcare-plan-affordability-aca/809779/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Tecvayli tops standard drugs in early multiple myeloma, J&amp;J says
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-15 16:32</span>
                        
                    </div>
                    
                    <p class="news-summary">The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&amp;amp;J a new kind of drug review voucher.&amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/news/johnson-johnson-tecvayli-early-multiple-myeloma-majestec-results/809721/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Oxford Biomedica confirms takeover talks with biotech investor EQT
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-15 16:06</span>
                        
                    </div>
                    
                    <p class="news-summary">Oxford, major contract manufacturer to cell and gene therapy companies, has already rejected multiple, unsolicited take-private bids from EQT that it felt &amp;ldquo;undervalued&amp;rdquo; the company and its prospects.</p>
                    
                    <a href="https://www.biopharmadive.com/news/oxford-biomedica-eqt-offer-acquire-cell-gene-therapy/809705/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Boston Scientific to acquire Penumbra for $14.5B
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-15 15:47</span>
                        
                    </div>
                    
                    <p class="news-summary">With the planned purchase, Boston Scientific will gain a portfolio of devices to remove clots from blood vessels.</p>
                    
                    <a href="https://www.biopharmadive.com/news/boston-scientific-acquire-penumbra/809737/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Caldera starts up with $112.5M and a dual-targeting immune drug from China
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-14 15:50</span>
                        
                    </div>
                    
                    <p class="news-summary">The biotech is advancing a bispecific medicine aimed at two popular targets and being billed as a potential therapeutic advance for inflammatory bowel disease.</p>
                    
                    <a href="https://www.biopharmadive.com/news/caldera-biotech-startup-qyuns-ibd-drug-tl1a-il23/809577/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-13">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        JPM26: Biotechâ€™s M&amp;A lift, the â€˜newâ€™ Biogen and Merckâ€™s $70B target
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-13 21:45</span>
                        
                    </div>
                    
                    <p class="news-summary">Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all approaching crucial trial readouts.</p>
                    
                    <a href="https://www.biopharmadive.com/news/jpm26-biogen-gilead-merck-cidara-moderna-summit/809446/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-17">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        JPM recap; Mirador raises $250M; Genentechâ€™s PBM shift; and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-17 11:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Welcome back to Endpoints Weekly! One programming note before we dive into news from #JPM26: We wonâ€™t be sending newsletters on Monday, but weâ€™ll be back in your inbox on Tuesday. The Endpoints News ...</p>
                    
                    <a href="https://endpoints.news/jpm-recap-mirador-raises-250m-genentechs-pbm-shift-and-more/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Supreme Court will hear Hikmaâ€™s â€˜skinny labelâ€™ fight against Amarin
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 20:06</span>
                        
                    </div>
                    
                    <a href="https://endpoints.news/supreme-court-will-hear-hikmas-skinny-label-fight-against-amarin/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        #JPM26: Sandoz CEO on Ozempic generic launch plans for 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 14:42</span>
                        
                    </div>
                    
                    <p class="news-summary">SAN FRANCISCO â€” Throughout his 53 meetings at this year&#39;s JPMorgan Healthcare Conference, Richard Saynor mulled a charitable idea about the topic on everyone&#39;s minds. &#34;We&#39;re going to put a cup in the middle of ...</p>
                    
                    <a href="https://endpoints.news/jpm26-sandoz-ceo-on-ozempic-generic-launch-plans-for-2026/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 12:00</span>
                        
                    </div>
                    
                    <p class="news-summary">â†’ These days, itâ€™s just not Peer Review without Novo Nordisk: Anja Leth Zimmer said on LinkedIn that she had been promoted to chief AI officer at the Danish pharma, which ...</p>
                    
                    <a href="https://endpoints.news/novo-nordisk-biomarin-make-ai-moves-bristol-myers-welcomes-neurology-exec-from-eisai/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        New York sues ex-Emergent CEO over insider trading during vaccine manufacturing struggle
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-15 20:36</span>
                        
                    </div>
                    
                    <p class="news-summary">New York prosecutors sued the former CEO of Emergent BioSolutions over alleged insider trading while the contract manufacturer struggled with contamination issues making AstraZeneca&#39;s Covid-19 vaccine during the pandemic. The lawsuit ...</p>
                    
                    <a href="https://endpoints.news/new-york-sues-ex-emergent-ceo-over-insider-trading-during-vaccine-manufacturing-struggle/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Trump asks Congress to codify â€˜most favored nationâ€™ deals
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-15 19:10</span>
                        
                    </div>
                    
                    <p class="news-summary">President Donald Trump wants new legislation that cements his &#34;most favored nation&#34; deals with drugmakers, asking Congress to put the drug price discounts into law that the pharma industry has so far voluntarily agreed to ...</p>
                    
                    <a href="https://endpoints.news/trump-asks-congress-to-codify-most-favored-nation-deals/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-15 17:42</span>
                        
                    </div>
                    
                    <p class="news-summary">Eli Lilly and Novo Nordisk have waged a bitter legal campaign against compounding pharmacies that have churned out custom versions of their blockbuster obesity drugs over the last couple of years. Now, one is fighting ...</p>
                    
                    <a href="https://endpoints.news/a-compounding-pharmacy-hits-back-at-eli-lilly-novo-nordisk-with-antitrust-lawsuit/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        #JPM26: Inside Fosun Pharma&#39;s ambition to reach outside of China
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-15 16:31</span>
                        
                    </div>
                    
                    <p class="news-summary">SAN FRANCISCO â€” Shanghai Fosun Pharmaceutical, a major Chinese healthcare manufacturer, aims to build itself into a global drug innovator, an executive with the company told Endpoints News at the JP Morgan Healthcare Conference. ...</p>
                    
                    <a href="https://endpoints.news/inside-fosun-pharmas-ambition-to-reach-outside-of-china/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Alfasigma gains neuro treatment; BridgeBio offers $550M in notes
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-15 15:48</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus, news about Insmed: ğŸ§  Alfasigma strikes deal for neurological disease treatment: The pharma company has secured global rights to the parenteral formulation of Innovative Moleculesâ€™ drug candidate adibelivir for Herpes ...</p>
                    
                    <a href="https://endpoints.news/alfasigma-gains-neuro-treatment-bridgebio-offers-550m-in-notes/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        #JPM26: Manufacturers benefit as pharma customers invest back in US
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-14 20:19</span>
                        
                    </div>
                    
                    <p class="news-summary">The tariff and trade policy changes that made 2025 so tumultuous for pharmaceutical companies are shaping up to bring benefits in the year ahead now that there&#39;s more clarity, according to manufacturers at the annual ...</p>
                    
                    <a href="https://endpoints.news/manufacturers-benefit-as-pharma-customers-invest-back-in-us/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Jazz sells priority review voucher for $200M, scoring highest price in a decade
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-14 18:44</span>
                        
                    </div>
                    
                    <p class="news-summary">Jazz Pharmaceuticals said it sold a priority review voucher to an undisclosed company for $200 million, landing the highest price for such a voucher since 2016. Jazz will take home half ...</p>
                    
                    <a href="https://endpoints.news/jazz-sells-priority-review-voucher-for-200m-scoring-highest-price-in-a-decade/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç›‘ç®¡å®¡æ‰¹</h2>
                    <span class="category-title-en">Regulatory</span>
                    <span class="category-count">20 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Verified Clinical Benefit | Cancer Accelerated Approvals
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 15:17</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.</p>
                    
                    <a href="http://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Safety Oversight Board
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 21:17</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The DSB is composed of representatives from two FDA Centers and eight other federal government agencies, the Agency for Healthcare Research and Quality, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, Department of Defense.</p>
                    
                    <a href="http://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/drug-safety-oversight-board" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Patient Listening Session Summaries
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 21:13</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Public Engagement Staff draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.</p>
                    
                    <a href="http://www.fda.gov/patients/fda-patient-listening-sessions/patient-listening-session-summaries" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Resources for Biomarker Requestors
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 21:11</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Information and resources for requestors about FDAâ€™s Biomarker Qualification Program</p>
                    
                    <a href="http://www.fda.gov/drugs/biomarker-qualification-program/resources-biomarker-requestors" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Tips for Section 804 Importation Program Proposals (SIPs)
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 18:39</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDAâ€™s tips for section 804 state importation program (SIP) proposals provide information to assist states and tribes develop their proposals.</p>
                    
                    <a href="http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/tips-section-804-importation-program-proposals-sips" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Section 804 Importation Program Policies and Authorizations
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 17:17</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA has issued policies and taken actions to implement section 804 of the Federal Food, Drug and Cosmetic Act, which allows states and Indian tribes to import certain prescription drugs from Canada. Learn more.</p>
                    
                    <a href="http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/section-804-importation-program-policies-and-authorizations" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Section 804 Importation Program (SIP) Proposals and FDAâ€™s Review Process
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 17:13</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Section 804 of the Federal Food, Drug and Cosmetic Act allows states and Indian tribes to import certain prescription drugs from Canada to significantly reduce the cost of these drugs without imposing additional risk to public health and safety.</p>
                    
                    <a href="http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/section-804-importation-program-sip-proposals-and-fdas-review-process" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Importation Program under Section 804 of the FD&amp;C Act
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 17:13</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA has developed a pathway under section 804 of the Federal Food, Drug, and Cosmetic Act (FD&amp;amp;C Act) that allows states and Indian tribes to import certain prescription drugs from Canada. Learn more.</p>
                    
                    <a href="http://www.fda.gov/drugs/human-drug-imports/importation-program-under-section-804-fdc-act" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA Authorizes Floridaâ€™s Drug Importation Program
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 17:04</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA authorized Floridaâ€™s Agency for Health Care Administrationâ€™s Section 804 Importation Program (SIP) in accordance with section 804 of the Federal Food, Drug, and Cosmetic Act (FD&amp;amp;C Act) and the FDAâ€™s implementing regulations.</p>
                    
                    <a href="http://www.fda.gov/news-events/press-announcements/fda-authorizes-floridas-drug-importation-program" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        State Importation Program Enhancements
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 16:54</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA is committed to continuing to work with states and Indian tribes that seek to develop an importation proposal under section 804 of the Federal Food, Drug and Cosmetic Act.</p>
                    
                    <a href="http://www.fda.gov/about-fda/reports/state-importation-program-enhancements" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drugs@FDA Data Files
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 15:01</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        My Dog Has Cancer: What Do I Need to Know?
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 13:44</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Just as FDA reviews drugs for humans for safety and effectiveness before they can go on the market, the agency does the same for treatments for animals. Learn how FDA brings new oncology treatments to market and questions to ask your vet about your dog&#39;s cancer diagnosis.</p>
                    
                    <a href="http://www.fda.gov/consumers/consumer-updates/my-dog-has-cancer-what-do-i-need-know" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Field Science - Laboratory Manual
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-15 20:02</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The Laboratory Manual is a reference manual for FDA personnel. It provides FDA personnel with information on internal procedures to be used as an agency policy for testing consumer products, training of laboratory staff, report writing, safety, research, review of private laboratory reports and cour</p>
                    
                    <a href="http://www.fda.gov/science-research/field-science-and-laboratories/field-science-laboratory-manual" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Reviews of Pediatric Studies Conducted under BPCA and Pediatric assessments conducted under PREA from 2012 â€“ present
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 18:40</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The following are the medical, statistical, and clinical pharmacology reviews of pediatric studies conducted in response to a Written Request issued under the BPCA and pediatric assessments conducted under PREA.</p>
                    
                    <a href="http://www.fda.gov/drugs/development-resources/reviews-pediatric-studies-conducted-under-bpca-and-pediatric-assessments-conducted-under-prea-2012" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug User Fee Amendments
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 23:19</span>
                        
                    </div>
                    
                    <p class="news-summary">This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.</p>
                    
                    <a href="http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Section 804 Importation Program Quality Assurance Tool
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 17:14</span>
                        
                    </div>
                    
                    <p class="news-summary">This quality assurance (QA) tool is designed to assist section 804 importation program (SIP) sponsors prepare proposals that fully comply with the requirements under the final rule.</p>
                    
                    <a href="http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/section-804-importation-program-quality-assurance-tool" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Human Drug Imports
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 16:53</span>
                        
                    </div>
                    
                    <p class="news-summary">Human drug import information including PLAIR, safe importation action plan, and personal importation policy.</p>
                    
                    <a href="http://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-imports" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Recently Issued Guidance Documents
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 15:59</span>
                        
                    </div>
                    
                    <p class="news-summary">This page lists Recently Issued CBER and Cross-Center Guidance Documents.</p>
                    
                    <a href="http://www.fda.gov/vaccines-blood-biologics/biologics-guidances/recently-issued-guidance-documents" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug Facilities, Sites and Organization Lists
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-16 14:47</span>
                        
                    </div>
                    
                    <p class="news-summary">Generic Drug Facilities, Sites and Organization Lists</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Office of New Drugs Custom Medical Queries (OCMQs)
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-15 20:43</span>
                        
                    </div>
                    
                    <p class="news-summary">Office of New Drugs Custom Medical Queries (OCMQs) are standardized groupings of similar adverse event terms intended to assist with the identification of potential safety issues during review of adverse event data.</p>
                    
                    <a href="http://www.fda.gov/drugs/development-resources/office-new-drugs-custom-medical-queries-ocmqs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">å•†ä¸šåŠ¨æ€</h2>
                    <span class="category-title-en">Business/M&amp;A</span>
                    <span class="category-count">7 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Argenx receives review from FDA for VYVGART in seronegative gMG
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-14 11:54</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Regulator accepts supplemental application supported by positive phase 3 data</p>
                    
                    <a href="https://pharmatimes.com/news/argenx-receives-review-from-fda-for-vyvgart-in-seronegative-gmg/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-14">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        PMGroup Worldwide Ltd welcomes MAD World Summit
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-14 12:01</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Acquisition expands PMGroupâ€™s commitment to transforming workplace health and organisational resilience</p>
                    
                    <a href="https://pharmatimes.com/news/pmgroup-worldwide-ltd-welcomes-mad-world-summit/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-13">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Nuclera extends Series C funding to advance antibody engineering
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-13 13:52</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Investment to accelerate development of fullâ€‘format antibody capabilities on eProtein Discovery system</p>
                    
                    <a href="https://pharmatimes.com/news/nuclera-extends-series-c-funding-to-advance-antibody-engineering/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Ipsen announces new data on Dysport in neurological disease
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-15 12:55</span>
                        
                    </div>
                    
                    <p class="news-summary">Dysport reduces muscle contractions by blocking the transmission of nerve impulses</p>
                    
                    <a href="https://pharmatimes.com/news/ipsen-announces-new-data-on-dysport-in-neurological-disease/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Jurgen Berendsen
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-15 12:54</span>
                        
                    </div>
                    
                    <p class="news-summary">Symeres has appointed Jurgen Berendsen as Chief Financial Officer (CFO).</p>
                    
                    <a href="https://pharmatimes.com/appointments/jurgen-berendsen/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        True colours
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-15 10:09</span>
                        
                    </div>
                    
                    <p class="news-summary">The gold standard in spectroscopy</p>
                    
                    <a href="https://pharmatimes.com/web_exclusives/true-colours/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-13">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-13 10:53</span>
                        
                    </div>
                    
                    <p class="news-summary">New manufacturing technologies aim to accelerate next-generation cell therapy development</p>
                    
                    <a href="https://pharmatimes.com/news/cellistic-launches-new-ipsc-based-platforms-to-expand-immuno-oncology-therapies/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
        </main>

        <footer>
            <p>Generated by <strong>Pharma Daily</strong> - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ</p>
            <p>2026-01-19 23:31</p>
        </footer>
    </div>

    <script>
    (function() {
        const filterBtns = document.querySelectorAll('.date-btn');
        const newsCards = document.querySelectorAll('.news-card');
        const filterCount = document.getElementById('filterCount');
        const categories = document.querySelectorAll('.category');

        function updateFilter(selectedDate) {
            let visibleCount = 0;

            newsCards.forEach(card => {
                const cardDate = card.getAttribute('data-date');
                if (selectedDate === 'all' || cardDate === selectedDate) {
                    card.classList.remove('hidden');
                    visibleCount++;
                } else {
                    card.classList.add('hidden');
                }
            });

            // Hide empty categories
            categories.forEach(category => {
                const visibleCards = category.querySelectorAll('.news-card:not(.hidden)');
                category.style.display = visibleCards.length > 0 ? 'block' : 'none';

                // Update category count
                const countSpan = category.querySelector('.category-count');
                if (countSpan) {
                    countSpan.textContent = visibleCards.length + ' æ¡';
                }
            });

            // Update filter count display
            if (selectedDate === 'all') {
                filterCount.textContent = '';
            } else {
                filterCount.textContent = `æ˜¾ç¤º ${visibleCount} æ¡æ–°é—»`;
            }
        }

        filterBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                filterBtns.forEach(b => b.classList.remove('active'));
                this.classList.add('active');
                updateFilter(this.getAttribute('data-filter'));
            });
        });
    })();
    </script>
</body>
</html>